Celltrion, Inc. Stock Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
Sales 2024 * | 3,485B 2.52B | Sales 2025 * | 4,155B 3.01B | Capitalization | 36,261B 26.25B |
---|---|---|---|---|---|
Net income 2024 * | 540B 391M | Net income 2025 * | 1,100B 796M | EV / Sales 2024 * | 10.6 x |
Net Debt 2024 * | 721B 522M | Net cash position 2025 * | 106B 76.39M | EV / Sales 2025 * | 8.7 x |
P/E ratio 2024 * |
69.5
x | P/E ratio 2025 * |
33.9
x | Employees | - |
Yield 2024 * |
0.25% | Yield 2025 * |
0.27% | Free-Float | 66.01% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B | |
-11.83% | 10.8B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock